Zileuton™ loaded in polymer micelles effectively reduce breast cancer circulating tumor cells and intratumoral cancer stem cells.
Cancer stem cells (CSC)
Circulating tumor tells (CTC)
Nanomedicine
Polymeric micelles
Zileuton™
Journal
Nanomedicine : nanotechnology, biology, and medicine
ISSN: 1549-9642
Titre abrégé: Nanomedicine
Pays: United States
ID NLM: 101233142
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
15
03
2019
revised:
28
08
2019
accepted:
01
10
2019
pubmed:
2
11
2019
medline:
13
11
2020
entrez:
1
11
2019
Statut:
ppublish
Résumé
Tumor recurrence, metastatic spread and progressive gain of chemo-resistance of advanced cancers are sustained by the presence of cancer stem cells (CSCs) within the tumor. Targeted therapies with the aim to eradicate these cells are thus highly regarded. However, often the use of new anti-cancer therapies is hampered by pharmacokinetic demands. Drug delivery through nanoparticles has great potential to increase efficacy and reduce toxicity and adverse effects. However, its production has to be based on intelligent design. Likewise, we developed polymeric nanoparticles loaded with Zileuton™, a potent inhibitor of cancer stem cells (CSCs), which was chosen based on high throughput screening. Its great potential for CSCs treatment was subsequently demonstrated in in vitro and in in vivo CSC fluorescent models. Encapsulated Zileuton™ reduces amount of CSCs within the tumor and effectively blocks the circulating tumor cells (CTCs) in the blood stream and metastatic spread.
Identifiants
pubmed: 31666201
pii: S1549-9634(19)30190-X
doi: 10.1016/j.nano.2019.102106
pii:
doi:
Substances chimiques
Micelles
0
zileuton
V1L22WVE2S
Hydroxyurea
X6Q56QN5QC
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102106Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.